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OPEN
SHORT COMMUNICATION
Autoimmunity to HSP60 during diet induced obesity in mice
ME Şelli1, G Wick2, DC Wraith3,4 and AC Newby1
Adaptive immunity has been implicated in adipose tissue inﬂammation, obesity and its adverse metabolic consequences. No
obesity-related autoantigen has yet been identiﬁed, although heat shock protein 60 (HSP60) has been implicated in other
autoimmune diseases. We investigated whether feeding a high-fat diet to C57BL/6J mice would cause autoimmunity to HSP60 and
whether immunomodulation with peptides from HSP60 would reverse the resulting obesity or metabolic dysfunction. Obese mice
had higher circulating levels of HSP60 associated with increased T-lymphocyte proliferation responses and the emergence of
circulating IgG1 and IgG2c antibody levels against HSP60. Treatment with escalating doses of a mixture of three proven
immunomodulatory HSP60 peptides did not reduce weight but completely reversed the increase in VLDL/LDL levels and partially
reversed the glucose intolerance in obese mice. Obese mice mount an autoimmune response to HSP60, which partly underlies the
resulting metabolic disturbances.
International Journal of Obesity (2017) 41, 348–351; doi:10.1038/ijo.2016.216
INTRODUCTION
Obesity is increasing worldwide, accompanied by rising levels of
type-2 diabetes and the metabolic syndrome, fatty liver disease,
breast and colon cancer, musculoskeletal disorders and cardio-
vascular diseases, including atherosclerosis and stroke.1,2 Many
harmful effects of obesity have been attributed to adipose tissue
(AT) inﬂammation,3 with both innate and adaptive immunity
implicated.4 The evidence that T lymphocytes contribute to AT
inﬂammation includes: (1) T cells accumulate in AT even before
macrophages.5–7 (2) Restricted Vα repertoires imply antigen-
speciﬁc clonal expansion.8 (3) Deletion of MHC Class II molecules
globally or on macrophages reduces obesity, insulin resistance
and AT inﬂammation.9,10 (4) Conversely, enhancement of antigen-
presenting cell function favours AT inﬂammation and promotes
insulin resistance.11 This evidence suggests an autoimmune
component in obesity but no culprit autoantigens have so far
been identiﬁed.
HSP60 is an evolutionarily conserved mitochondrial chaperonin
that can translocate to the cytosol and cell membrane and be
released into the circulation under conditions of stress.12 HSP60
has been associated with the autoimmune component of several
inﬂammatory diseases, including atherosclerosis.12 More recently,
release of HSP60 from AT was demonstrated as well as its ability to
cause insulin resistance and pro-inﬂammatory cytokine (TNF-α,
IL-6 and IL-8) release by adipocytes.13 Also, circulating HSP60
levels were found higher in obese individuals than lean controls.13
All these observations make HSP60 a candidate autoantigen in
obesity, although this has not yet been demonstrated. We
therefore investigated whether high-fat diet (HFD) feeding gives
rise to autoimmunity against HSP60 in mice and whether
immunomodulation with HSP60-speciﬁc peptides can reduce
obesity or the related metabolic impairment.
MATERIALS AND METHODS
More detail is given in the Supplementary Methods ﬁle available at
the International Journal of Obesity’s website. Brieﬂy: C57BL/6J mice
(6 weeks old) purchased from Charles River Laboratories (Margate,
UK) were fed normal chow (ND) or a HFD supplemented with 21%
lard and 0.15% cholesterol (Special Diets Services, Witham, Essex,
UK) for 16–20 weeks to induce obesity. For peptide treatment, 6-
week-old mice were pre-dosed subcutaneously with HSP60 peptides
(GL Biochem, Shanghai, China) starting at 0.1 μg per mouse. The
dose was increased 10-fold every week up to 100 μg per mouse,
which was given weekly three more times, then every 2 weeks until
the end of study. HFD was started at 11 weeks of age (after the third
top dose) and lasted for 20 weeks14 when killed by cervical
dislocation under Home Ofﬁce Licence 70/22957. The Guide for the
care and use of laboratory animals, Eighth edition (2011) (http://
grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-labora
tory-animals.pdf) was followed. Procedures were carried out
under Home Ofﬁce Licences 30/3064 and 70/22957. All animals
survived until killed and were included in the analysis.
After killing, epididymal fat pads were collected, weighed and the
stromal vascular fraction (SVF) was isolated by collagenase digestion.
For analysis of macrophage populations, 1 million SVF cells were
examined by ﬂow cytometry analysis using antibodies against
CD11b, F4/80, CD11c and CD206. T-cell populations were analysed
using antibodies against CD45, CD3ε, CD4, CD25 and FoxP3.
Serum HSP60 levels were measured with a mouse HSP60 ELISA
(NeoScientiﬁc, Cambridge, MA, USA). Serum anti-HSP60 antibody
levels were measured with a custom-made ELISA using recombi-
nant, endotoxin-depleted murine HSP60 protein (Enzo Life
Sciences, Farmingdale, NY, USA) bound to Nunc Immuno
MaxiSorp 96-well plates. For the HSP60 reactive T-cell proliferation
assay, total cell pellets from homogenised spleens were pulsed
with 3H-thymidine for 18 h after pre-treating with buffer control,
recombinant HSP60 or peptides.
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Glucose tolerance tests were performed after 16 weeks of ND or
HFD. After 6 h fast, 2 g kg−1 body weight of glucose was injected
intraperitoneally and glucose concentration in blood from tail snips
was measured 0, 15, 30, 60 and 90 min later. Insulin tolerance test
was conducted one week later. After 4 h fast, rapid acting human
insulin (NovoRapid; Novo Nordisk A/S, Bagsvaerd, Denmark) was
injected intraperitoneally to give a ﬁnal dose of 1 U kg−1 body
weight. Blood glucose was measured at the same time points. Mouse
Ultrasensitive Insulin ELISA kit (Alpco, Salem, NH, USA) was used to
determine fasting insulin levels.
For normally distributed variables (Kolmogorov–Smironov test),
a two-tailed, unpaired Student’s t-test was used to determine
signiﬁcant differences between 2 means. For multiple compar-
isons, a one-way ANOVA or two-way ANOVA was performed, as
appropriate, followed by a Bonferroni correction. Differences were
considered signiﬁcant if Po0.05.
RESULTS
Increased circulating HSP60 levels, antibodies against HSP60, and
T-cell responses to HSP60 in HFD-fed C57BL/6J mice
C57BL/6J mice fed HFD for 16 weeks were 3 g heavier than
ND mice (Figure 1a) and their epididymal fat pads were almost
three times heavier (Figure 1b). Plasma levels of LDL/VLDL were
signiﬁcantly increased (74%) by HFD, although HDL levels were
unaltered (Figure 1c). HFD signiﬁcantly increased circulating
HSP60 levels by 12% (Figure 1d), suggesting that obesity is a
stress factor capable of stimulating HSP60 release.
As evidence for an autoimmune reaction to HSP60, recombinant
HSP60 increased splenic T-lymphocyte proliferation relative to buffer
controls by 20–40% more in HFD than ND mice. This increase was
signiﬁcant at 0.1 and 10 μgml−1 and it was at borderline signiﬁcance
(P=0.063) at 1.0 μgml−1 concentration (Figure 1e). The response to
HSP60 was much weaker than the positive control ConA (13-fold,
not shown), not surprisingly because the mice were not hyper-
immunized. Circulating anti-HSP60 levels were undetectable in ND
mice but HFD signiﬁcantly elevated both anti-HSP60 IgG1, which is
mainly dependent on Thelper2 (Th2) lymphocytes, and IgG2c, which
is driven by Th1 lymphocytes15 (Figure 1f). Differences between HFD
and NDmice were highly signiﬁcant above 1/16 dilution; much lower
than expected for hyper-immune serum (typically41/1000). Clearly,
short periods of obesity triggered autoimmunity against murine
HSP60, albeit at low level.
Effect of HSP60 peptide treatment on obesity and related
metabolic dysfunction
To investigate the impact of HSP60 autoimmunity, we used
subcutaneous HSP60 peptide treatment with a combination of
equal concentrations of three peptides known to cause favourable
immunomodulation in models of autoimmune diabetes
or atherosclerosis. These were vlgggcallrcipaldslkpaned,16
Figure 1. Effect of HFD on weight gain, metabolism and autoimmunity to HSP60. Groups of mice (n=7) were fed HFD or ND for 16 weeks.
(a) Body weights (P=0.007) and (b) epididymal fat pad weights (P=0.004) were signiﬁcantly increased by HFD. (c) Circulating LDL/VLDL levels were
also signiﬁcantly increased (P=0.005). (d) Mouse HSP60 levels measured in serum samples by ELISA were signiﬁcantly higher in HFD compared with
ND fed mice (P=0.039; n=19 each). (e) T-cell proliferation (expressed relative to the medium alone negative control) increased signiﬁcantly in HFD
compared with ND splenoctes when stimulated by 0.1 μg ml−1 (P=0.013) or 10 μg ml−1 (P=0.038) of recombinant mouse HSP60. (f) Both anti-
HSP60 IgG1 and IgG2c circulating antibody levels were signiﬁcantly elevated by HFD (Pmax=0.008 for IgG1; Pmax=0.00009 for IgG2c).
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aelkkqskpvt17 and dgealstlvlnrlkvg.18 Each of these peptides had
good solubility in water (results not shown). We used a dose
escalation protocol that has proved safe and effective against
experimental autoimmune encephalomyelitis.14
HSP60 peptide treatment did not reverse HFD-induced weight
gain (Figure 2a) or the increase in epididymal fat mass (Figure 2b),
which were greater in this experiment owing to the longer period
of HFD feeding. However, peptide treatment reversed the
signiﬁcantly increased circulating LDL/VLDL levels in HFD mice
(Figure 2c).
Glucose tolerance was signiﬁcantly impaired in HFD compared to
ND mice. HSP60 peptide treatment rendered HFD mice signiﬁcantly
more glucose tolerant, although not as tolerant as ND mice
(Figure 2d). Fasting insulin levels were elevated to the same degree
Figure 2. Effect of HSP60 peptide treatment on obesity, metabolic dysfunction and autoimmunity to HSP60. (a) Mice (n=14) given HFD or HFD with
HSP60 peptides increased weight to the same extent relative to ND (P=0.000002 for HFD, P=0.00045 for HSP60). (b) Epididymal fat pad weights
were similarly doubled by HFD or HFD with HSP60 peptides (P=0.0012 for HFD, P=0.00009 for HSP60). (c) HFD increased LDL/VLDL (P=0.0003)
and HDL levels (P=0.00045) and the HSP60 treatment signiﬁcantly normalised LDL/VLDL levels (P=0.0088) but not HDL levels. (d) HFD signiﬁcantly
impaired glucose tolerance (P=3.4×10−18, two-way ANOVA) and the impairment was partially but signiﬁcantly reversed by HSP60 peptide
treatment (P=0.0079). In a subgroup (n=7 each): (e) no differences were found in insulin tolerance between the three groups. (f) From ﬂow
cytometry, epididymal stromal vascular fraction CD45+CD11b+F4/80+ macrophages were increased (P=0.013) and (g) CD45+CD3+CD4+CD25+
Foxp3+ regulatory T cells were decreased signiﬁcantly (P=0.003) with HFD or HFD plus HSP60 peptides. (h) There was an increase in the level of
anti-HSP60 IgG1 antibodies observed in both HFD groups, but only the increase in the peptide treatment group was signiﬁcant (P=0.022). (i) Anti-
HSP60 IgG2c antibodies were increased in HFD mice, but this was signiﬁcant only in the HFD alone group (P=0.048 for 1/16 dilution).
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relative to ND (0.64±0.05 ng ml−1) by HFD, irrespective of peptide
treatment (1.01±0.22 and 1.18±0.22 ngml−1) and could not
account for the improved glucose tolerance. Insulin sensitivity,
measured in an insulin tolerance test, was also similar in ND, HFD and
peptide treatment groups (Figure 2e).
To investigate whether HSP60 peptide treatment suppressed
obesity-associated inﬂammation, we subjected SVF cells to ﬂow
cytometry. We recorded a signiﬁcant increase in macrophages
(Figure 2f), no change in total CD4+ or CD4− T lymphocytes (not
shown) and a decrease in Treg cells (Figure 2g) in HFD compared
with ND mice but there was no effect of HSP60 peptide treatment
(Figures 2f and g). We also did not observe any difference in splenic
T-cell proliferation responses to recombinant HSP60 in HFD-fed mice
with and without HSP60 peptide treatment. Nor did we ﬁnd any
difference in the levels of IL-2, IL-4, IL-6, IL-10, IL-17, IFN-γ or TNFα
released spontaneously or in response to HSP60 challenge (results
not shown). However, HSP60 peptide treatment increased the titre of
anti-HSP60 IgG1 (Figure 2h) but not IgG2c antibodies (Figure 2i),
which implies an enhancement of Th2-driven antibody production.
DISCUSSION
An autoimmune component of obesity has been postulated8,9 (see
Introduction) but our study is the ﬁrst to identify a contributing
autoantigen. Obese mice clearly mounted a weak autoimmune
response to HSP60 at both the T- and B-cell levels after a short period
of HFD. Consistent with this, lean humans have antibodies to HSP60,
presumably arising from other stressors,12 but the level of auto-
antibodies is increased by obesity that is clearly much more prolonged
than in our mice.13 Moreover, we could reverse the hypercholester-
olaemic effect of HFD and partially improve glucose tolerance with
immunomodulatory HSP60 peptide treatment, implying that auto-
immunity to HSP60 contributed to the metabolic disturbances caused
by obesity, despite weight not being reduced. A similar decoupling of
obesity and metabolic disturbances has been noted in other studies
when suppressing adaptive immunity, for example in RAG-1-deﬁcient
mice, which lack mature T and B lymphocytes.8 Given observations
that LDL production is increased by obesity19 and that HSP60
autoimmunity contributes to atherosclerosis,12 the reduction in LDL
levels achieved by HSP60 peptide treatment is of interest. A recent
study showing that regulatory T cells can reduce the levels of blood
cholesterol in low density lipoprotein deleted mice might provide a
mechanisms for our results,20 but this requires further investigation.
HFD increased AT macrophages and decreased Treg as previously
reported by others (reviewed by Lolmede et al.4) but we did not see
any changes with HSP60 peptide treatment. Neither did we ﬁnd any
inﬂuence of peptide-induced splenic T-cell proliferation or cytokine
release. We did, however, see a switch towards Th2-driven IgG1
production, which implies that HSP60 peptide treatment caused
immunomodulation rather than immune tolerization, which will
require more extensive investigation. In summary, we showed for the
ﬁrst time that low-level autoimmunity to HSP60 contributes to, and
HSP60 peptide treatment partially reverses, metabolic disturbances in
a murine obesity model.
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